EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer

Jacek Kabut, Anita Gorzelak-Magiera iD, Iwona Gisterek-Grocholska iD

International Journal of Molecular Sciences · 25.04.2025 · 26 (9) · 4096

DOI: 10.3390/ijms26094096 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.04.2025. Verfasst von Jacek Kabut und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapy, Medical University of Silesia, 40-514 Katowice, Poland. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2, Lung Neoplasms, Receptors, Immunologic, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia, Katowice, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of immunotherapy and target therapy into clinical practice has become a chance for many patients with cancer to prolong their survival while maintaining optimal quality of life. Treatment of lung cancer is excellent evidence of the progress of medical therapies. An understanding of the mechanisms of tumor development has led to the evolution of new methods of treatment. Immunoreceptors of T cells with the immunoglobulin domain ITIM, TIM-3 (T-cell immunoglobulin- and mucin domain-3-containing molecule 3), and LAG-3 (lymphocyte activation gene-3) represent new interesting therapeutic targets. The combination of anti-PD-1 and anti-CTLA-4 blockade has proven the possibility of strengthening the anti-tumor response by acting via two separate mechanisms. Adding additional checkpoints to the PD-1 blockade offers hope for further improvements in the effects of the treatment of patients and expanding the group responding to immunotherapy. This paper presents new promising molecular targets along with studies demonstrating the treatment results using them.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis A Virus Cellular Receptor 2Lung NeoplasmsReceptors, ImmunologicCarcinoma, Non-Small-Cell LungAntigens, CDHumansLymphocyte Activation Gene 3 ProteinImmunotherapyMolecular Targeted TherapyAnimals

Stichwörter der Autor:innen

LAG-3TIGITTIM-3immunotherapylung cancer

Substanzen

Hepatitis A Virus Cellular Receptor 2Receptors, ImmunologicHAVCR2 protein, humanLymphocyte Activation Gene 3 ProteinTIGIT protein, humanLag3 protein, humanAntigens, CD

Autor:innen und Institutionen

  • Department of Oncology and Radiotherapy, Medical University of Silesia, 40-514 Katowice, Poland.

ORCID-Profile: Anita Gorzelak-Magiera, Iwona Gisterek-Grocholska

Förderung

  • Medical University of Silesia, Katowice, Poland

Zitieren

APA

Kabut, J., Gorzelak-Magiera, A., & Gisterek-Grocholska, I. (2025). New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 26(9), 4096. https://doi.org/10.3390/ijms26094096

Vancouver

Kabut J, Gorzelak-Magiera A, Gisterek-Grocholska I. New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences. 2025;26(9):4096. doi:10.3390/ijms26094096

BibTeX
@article{Kabut2025,
  author = {Kabut, Jacek and Gorzelak-Magiera, Anita and Gisterek-Grocholska, Iwona},
  title = {New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {9},
  pages = {4096},
  doi = {10.3390/ijms26094096}
}
Kostenlos starten →